Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 09

612P - Sentinel lymph node detection and accuracy in vulvar cancer: Meta-analysis and systemic review

Date

10 Sep 2022

Session

Poster session 09

Topics

Tumour Site

Vulvar and Vaginal Cancers

Presenters

Hyun-woong Cho

Citation

Annals of Oncology (2022) 33 (suppl_7): S235-S282. 10.1016/annonc/annonc1054

Authors

H. Cho

Author affiliations

  • Obstetrics & Gynecology, Korea University Guro Hospital, 152-703 - Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 612P

Background

Based on previous publication including RCTs and meta-analysis, sentinel lymph node (SLN) biopsy in women with early vulvar cancer is considered as a safe and effective procedure which is alternative to inguinofemoral lymph node dissection. However, near infrared imaging with indocyanine green (ICG) injection has emerged recently. Moreover, meta-analysis has not been updated for six years. We conducted a meta-analysis to evaluate the accuracy of SLN biopsy in vulval cancer.

Methods

Relevant studies were identified using the PubMed, MEDLINE, and Cochrane databases. The outcomes of this study were detection rate, false negative rate and clinical accuracy of SLN biopsy with radiocolloid tracer, blue dye or ICG.

Results

Of the 887 references, 51 studies were included. Pooled per groin detection rate for SLN biopsy using radiocolloid tracer, ICG and blue dye were 0.96 (0.93-0.98), 0.90 (0.83-0.98) and 0.72 (0.62-0.81), respectively. In meta-regression, SLN biopsy using radiocolloid tracer or ICG or both is significant moderator for detection of SLN (p=0.013).

Conclusions

SLN biopsy using radiocolloid tracer, ICG is highly reliable and accurate in selected patients under strict protocol. The utilization of ICG for SLN sampling is feasible and promising in future.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.